ENTPD1 and cancer: We also assessed the expression of CD39, the rate-limiting enzyme in the conversion of ATP to immunomodulatory adenosine; of CD69, a membrane-bound, type II C-lectin receptor that marks early activation of different immune subsets [33]; and of the IL-7 receptor subunit-α (CD127), associated with chronic inflammation and poorer outcome in cancer patients [34].